Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics is expected to have a successful launch of their product VIZZ in the near-term, projected to reach approximately 25,000 paid prescriptions for the first quarter of 2026. Risks to their investment thesis and target price include potential failure to achieve peak commercial revenue estimates and securing necessary funding. A key question is how VIZZ's performance compares to that of AbbVie's VUITY, and how the initial launch trajectory will develop over the coming quarters.

Bears say

LENZ Therapeutics is facing significant challenges in driving sales for its VIZZ product, as it has struggled to gain traction in converting patients to filled prescriptions and building product familiarity and willingness to prescribe among eye care professionals. Despite the company's attempts to expand globally, there is no guarantee of market success in regions such as Europe, the Middle East, Latin America, and Asia. Additionally, the company's valuation and estimated future performance have been adjusted downwards, and there are potential risks to its investment thesis and target price, including failure to achieve peak revenue estimates and secure necessary capital funding.

LENZ has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 5 analysts, LENZ has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.